New data links GLP-1 agonists for weight loss with higher risk for pancreatitis, GI events

Use of glucagon-like peptide 1 agonists for weight loss compared with bupropion-naltrexone was associated with an increased risk for pancreatitis, gastroparesis and bowel obstruction but not biliary disease, researchers reported in JAMA.
“Given the wide use of these drugs, these adverse events, although rare, must be considered by patients thinking about using them for weight loss,” Mohit Sodhi, MSc, a fourth-year medical student at the University of British Columbia, said in a related press release. “The risk calculus will differ depending on whether a patient is using these

Use of glucagon-like peptide 1 agonists for weight loss compared with bupropion-naltrexone was associated with an increased risk for pancreatitis, gastroparesis and bowel obstruction but not biliary disease, researchers reported in JAMA.
“Given the wide use of these drugs, these adverse events, although rare, must be considered by patients thinking about using them for weight loss,” Mohit Sodhi, MSc, a fourth-year medical student at the University of British Columbia, said in a related press release. “The risk calculus will differ depending on whether a patient is using these